Corcept Therapeutics stock surges 107% despite Q1 revenue miss

Earnings
โดย Yahoo Finance·Read original
Summary · why it matters

Corcept Therapeutics reported first-quarter revenues of $164.9 million, a 4.9% year-on-year increase that fell 11.3% short of analyst expectations, yet its stock has surged 107% since the announcement to trade at $96.50. The company, which focuses on cortisol-modulating medications, achieved the highest full-year guidance raise among the ten branded pharmaceuticals stocks tracked but also had the weakest performance against analyst estimates. The broader group posted mixed results, with aggregate revenues beating consensus by 3.6% and share prices rising an average of 8.5% since reporting. Eli Lilly delivered the strongest quarter, with revenues of $19.8 billion up 55.5% year on year and a 13.7% beat, while Zoetis was the weakest, missing estimates and seeing its stock fall 31.7%.

Impact on stocks 5

Biotech & Genomic Medicine▲ · 3 stocks
Eli Lilly and Company
LLY
▲ PositiveDemandrelevance

Delivered strongest quarter with 55.5% revenue growth and 13.7% beat, cited as a positive example.

Health Care▼ · 1 stocks
Zoetis Inc
ZTS
▼ NegativeDemandrelevance

Weakest performer, missed estimates and stock fell 31.7%.

Aging Population▲ · 1 stocks
© 2026 MarketDXNews